About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State

NCT07242664·2 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Andre Feldmann
CONTACT
+49 (0) 2131 4018 409 149-1226-GZR-33@profil.com

Lead

Gan and Lee Pharmaceuticals, USA

Age

18–64

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

18-64 years of age
HbA1c \<= 9.0%.
Body Mass Index (BMI) between 18.5 and 29.0 kg/m\^2
treated with a stable insulin regimen for at least 2 months, in a dose \> 0.2 and \< 1.2 U/kg/day

You may not be if

blood pressure outside the range 90 to 140 mmHg (systolic) or 50 to 99 mmHg (diastolic)
clinically significant concomitant diseases
recurrent severe hypoglycemia (more than 1 severe hypoglycemic episode requiring assistance from another person within 180 days before screening)
hypoglycemia unawareness
estimated glomerular filtration rate (eGFR) \<60.0 mL/min/1.73 m2

The record

StatusRecruiting

PhasePhase 1

Taking part12

StartedOct 2025

UpdatedNov 21, 2025

Conditions

Type 1 Diabetes Mellitis

Where2

Profil Institut
Neuss, Germany
Profil
Neuss, Germany